Detail akcie Incyte online

Business Summary: Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Incyte Corp revenues increased 9% to $880.9M. Net income increased from $21.7M to $169.5M. Revenues reflect OPZELURA revenues segment increase of 52% to $85.7M, Milestone and contract revenues segment increase from $0K to $25M. Net income benefited from Unrealized gain (loss) on long term inve increase from $5.3M (expense) to $99.9M (income), Selling & General Expenses decrease of 12% to $194.7M (expense).